The efficacy of macrolides against extracellular pathogens depends on extracellular levels of free drug and the organisms' patterns of susceptibility to the macrolides. The effect of macrolides against most bacteria is considered time-dependent. The size of inoculum affects erythromycin's activity against streptococci and, moreover, against staphylococci. The optimal effect is observed at a pH of 8. A significant postantibiotic effect (PAE), lasting Ç9 hours, has been shown with erythromycin and roxithromycin against gram-positive cocci. Azalides share the same properties. For the streptogramin synercid, a dose-dependent bactericidal activity within a range of low concentrations has been demonstrated. The serum area under the curve appeared to be the best predictor of in vivo effect on the mouse thigh model. Synercid also exhibited a prolonged PAE (Ç10 hours) against the main pathogens of its spectrum. A better knowledge of the pharmacodynamic properties of macrolides and streptogramins is essential for definition of proper dosing regimens.
Macrolide antibiotics have been considered for many years RP 59500), a new semisynthetic injectable streptogramin that is a combination of two derivatives of pristinamycin I (RP to be safe and valuable for the treatment of various infections of the upper and lower respiratory tracts and of skin and soft 57669, or quinupristin) and pristinamycin II (RP 54476, or dalfopristin), exhibits attractive antibacterial activity through tissues, either as first-line therapy or as an alternative to penicillins for allergic patients. Moreover, in the past decade, interest the synergistic activity of its two components. This drug is currently undergoing phase III clinical trials. The potential in these agents has revived with the recognition and increasing prevalence of pathogens such as Legionella, Mycoplasma, interest in this compound concerns its activity against some gram-positive cocci otherwise resistant to macrolides [3] . Chlamydia, and Campylobacter species. Several new macrolide compounds -including the azalide azithromycin, a 15-memThere is a surprisingly limited amount of information regarding the pharmacodynamic properties of macrolides. The main bered molecule -with improved pharmacokinetics and more or less broader antibacterial activity than erythromycin have reason is that erythromycin is a compound of longstanding use for which basic preclinical information was not required appeared in recent years and have been submitted to laboratory and clinical investigations [1, 2] .
at the time it was marketed. The newest compounds have been more extensively studied in various more or less sophisTwo other types of compounds, the lincosamides and the streptogramins, although chemically unrelated but exhibiting ticated in vitro and in vivo models. This article reviews these investigations and focuses on similar modes of action and antibacterial spectrum, are classically considered together with the macrolides. Among lincothe properties of clinical relevance toward extracellular pathogens. Some effects, such as those on intestinal motility samides, lincomycin is now mainly of historical interest, and clindamycin remains of particular interest as therapy for anaeror related to pH, will not be discussed. obic and some parasitic infections.
No specific studies have addressed the pharmacodynamic Main Pharmacokinetic Properties properties of these compounds. However, their mode of action, close to that of macrolides, makes it likely that their It is important to briefly review the main kinetic properties pharmacodynamic properties are similar. Synercid (formerly of macrolides and derivatives in order to put them in the perspective of their pharmacodynamic profiles. The major drawback of earlier macrolides was their poor intestinal absorption, in addition to large interindividual and intraindividual variations, short half-life, high degree of binding to serum proteins
This article is part of a series of papers presented at a symposium entitled ''Pharmacodynamics of Antimicrobials'' that was held on 21 -23 July 1995 (mainly the a1 acid glycoprotein), and poor gastrointestinal in Québec City, Québec, Canada. This symposium was organized by the Intertolerance. [4] ). The asterisk indicates various erythromycin derivatives named from A to F. [6] . It is important to note wide variations in peak serum con-
The pharmacokinetic properties of the two components of synercid, given iv in a 30/70 ratio at 5-, 10-, and 15-mg/kg centrations, elimination half-life (t 1/2 b) values, and area under the curve (AUC) values [5] . In addition, differences in terms doses, have been studied in healthy volunteers [7] . Mean C max values (mg/mL) were 1.3, 2.4, and 3.3 for quinupristin and 5.1, of maximal concentration (C max ) have been described for the different erythromycin preparations [6] .
7.1, and 8.5 for dalfopristin. Elimination half-live (t 1/2 b) values ranged between 0.6 hour and 1 hour (quinupristin) and 0.3 All macrolides accumulate intracellularly, mainly in polymorphonuclear leukocytes and macrophages, and some have hour and 0.4 hour (dalfopristin). Plasma clearance was high for both compounds: 1 L/(hrkg) persistently high intracellular levels. It is therefore possible to distinguish three types of macrolides, in comparison with for quinupristin and 0.8 L/(hrkg) for dalfopristin. The plasma levels of dalfopristin active metabolite were 20% -45% of those erythromycin: (1) azithromycin, which has low extracellular levels, high intracellular penetration, and long extracellular and of the parent drug, showing a trend to increase with the dose. Therefore, it is important to point out that both components intracellular elimination half-lives; (2) roxithromycin, which has relatively high serum levels and a shorter half-life than exhibit different t 1/2 b values, which must be kept in mind in some difficult-to-treat situations; the optimal ratio between the azithromycin; and (3) clarithromycin, which has all the properties of both compounds. Some older compounds such as spitwo components must be maintained as long as possible at the site of infection during the interval between two doses. ramycin and josamycin are also in this intermediate position. [13] . In addition, azithrofect, mainly against streptococci. This means they are slowly mycin has been shown to have longer in vitro PAEs than bactericidal, with a poor influence of increasing concentrations erythromycin against H. influenzae, but similar values were on the rapidity and importance of killing.
reported against S. aureus and S. pneumoniae (Ç1.8 hours and Several factors influence the antibacterial effect [8] . The Ç2.3 hours, respectively) [14] . Increasing macrolide concensize of the inoculum affects the antistreptococcal effect and, trations and exposure time prolong the duration of PAE to moreover, the antistaphylococcal activity. In the presence of a point of maximum response [15] , with an excellent linear serum, the MIC of some macrolides (roxithromycin, rokitarelationship between the duration of PAE and the log of the mycin) against Streptococcus pyogenes increases onefold to concentration or exposure time. Azithromycin had a profourfold. In contrast, the MICs for Streptococcus pneumoniae nounced decrease in bactericidal activity when added during do not change.
the PAE phase [16] . The optimal effect is observed at a pH of 8, with a significant
The PAE of RP 59500 has been evaluated against a variety of decrease in efficacy at low pH values (õ6). The pH, variability bacteria, mainly staphylococci, pneumococci, and streptococci. of activity, serum effect, and activity of the metabolites are Whatever the criterion used to define this effect (time required among the most important factors to be controlled in the evaluaeither for the viable counts to increase by one log 10 or for bacteria tion of antibacterial activity of macrolides. For instance, most to regain their maximal rate of growth), PAE was constantly of the studies on anaerobes have missed some of the effects observed when concentrations greater than or equal to the MICs of macrolides, since incubation with CO 2 lowers the pH of the were used. The concentration of antibiotic was found to be a medium [8] .
more important parameter than the time of exposure in determinThe two components of RP 59500 are bacteriostatic against ing the importance of PAE [17] . For instance, after 30 minutes macrolide, lincosamide, streptogramin B (MLS B )-susceptible of exposure to 5 mg/mL, the PAE was 5-7.5 hours for most and MR-MLS B -inducibly resistant Staphylococcus aureus, staphylococci, 7-9 hours for S. pneumoniae, and ú18 hours for whereas the MLS B -constitutively resistant strains are resistant S. pyogenes [18] . In the presence of human serum, the duration to quinupristin [3] . Synergy between antibiotics in vitro is a of PAE against staphylococci was increased [19] . phenomenon found at concentrations close to the MIC, except
The in vivo PAE is generally evaluated on the neutropenic for strains with constitutive resistance. High-level resistance to mouse thigh-infection model. Clarithromycin and azithromycin quinupristin does not significantly reduce the activity of the have been shown to induce a longer in vivo PAE than erythrocombination, and generally the fractional inhibitory concentramycin [13, 14] . It is interesting to note that with use of azithrotion index is found to be õ0.5. When studied in vivo in experimycin against staphylococci, this difference was noted in vivo mental murine models of septicemia due to S. aureus and S.
despite similar in vitro PAE values for azithromycin and erythpneumoniae, the combination exhibited the highest effect with romycin. In the same model, RP 59500 had 10-hour and 9-quinupristin/dalfopristin ratios ranging from 16/84 to 92/8. hour in vivo PAEs, respectively, after single doses of S. aureus This wide range of ratios of both components has been conand S. pneumoniae (despite short exposure times) [20] . Data firmed in the rabbit endocarditis model, demonstrating the in obtained from other models, such as infected subcutaneous vivo synergistic effect of both compounds, despite a different fibrin clots [21] and mouse pneumococal pneumonia [22, 23] , pattern of distribution of the two labelled components throughalso established the reality of an in vivo PAE with macrolides out the infected vegetations [9] . The bactericidal effect of RP and streptogramins. 59500 against S. aureus appears to be time-dependent but not
Integration of pharmacokinetic/pharmacodynamic properconcentration-dependent, as neither quinupristin nor dalfopristies. The definition of E max , corresponding to the static dose tin alone is bactericidal against the organism [10] . RP 59500 following repeated injections of a compound at various interis more rapidly bactericidal against S. pneumoniae than against vals in the mouse thigh (and/or lung) infection model, provides S. aureus (1 hour vs. 6 hours) [11] and is slowly active against information on the overall in vivo consequences of pharmacoEnterococcus faecium [8] .
kinetic/pharmacodynamic parameters and allows quantification Postantibiotic effect. Postantibiotic effect (PAE) is a comof efficacy and potency. The lowest E max values found with mon feature of all macrolides. However, several factors may clarithromycin vs. erythromycin in this model (3.7 mg/[kgrd] affect the in vitro PAE of these drugs [12] . The duration of vs. 101 mg/[kgrd]) against S. pneumoniae, when both drugs this effect is longer with gram-positive cocci than with Haemowere given every 12 hours, reflect longer periods of time during which serum levels remained over the MIC in vivo [13] . philus influenzae and longer with streptococci than with staphy- The more recent data on PAE for a variety of antimicrobials 50% of E max , the dosing interval of RP 59500 had little impact [20] . The AUC in serum was the pharmacokinetic parameter and microorganisms provide theoretical rationale for either intermittent or more-continuous dosing of antimicrobials, dethat correlated best with in vivo efficacy. Thus, despite a short half-life, in vivo efficacy of the compound can be maintained pending on the offending microorganism and the drug to be given. An intermittent dosing regimen would apply primarily at wide dosing intervals through a prolonged in vivo PAE. In order to determine the microbiological and pharmacokito drug-organism combinations that exhibit a prolonged PAE. Conversely, more-continuous administration is required for netic parameters that best predicted the in vivo antistaphylococcal activity of the streptogramin RP 59500, Fantin et al.
[29] drug-organism combinations lacking a PAE.
The thigh-infection and pneumonitis models in leukopenic utilized a rabbit model of aortic endocarditis. They evaluated the activity of three regimens of quinupristin/dalfopristin mice are suitable for comparing the efficacy of the same amount of drug given by either more-continuous dosing regimens (evagainst five strains of S. aureus with various streptogramin Btype antibiotic resistance phenotypes and with susceptibility to ery 1 or 2 hours) or by discontinuous dosing regimens (every 4 hours to once daily) [24] . For instance, with erythromycin, streptogramin A-type antibiotics. Quinupristin/dalfopristin was as active as vancomycin against three strains that were susceptiwhich exhibits a prolonged PAE against S. pneumoniae, no major difference was observed between hourly and 6-hourly ble to its streptogramin-B component quinupristin (including one strain that was inducibly resistant to erythromycin) but had dosing regimens. On the other hand, the more-continuous dosing regimen was significantly more effective for penicillin G, significantly decreased activity against two strains that were resistant to quinupristin, in all quinupristin/dalfopristin regiwhich does not exhibit an in vivo PAE against S. pneumoniae in this model. At very high doses of penicillin G, equal efficacy mens tested. The AUC for quinupristin-dalfopristin in plasma, divided by the MIC of quinupristin, was the only parameter was observed, as serum levels above the MIC were constantly maintained with both regimens [25] .
retained by multilinear regression that predicted the in vivo activity of quinupristin/dalfopristin, a finding emphasizing the The mouse models of S. pneumoniae and H. influenzae infections have provided interesting data for better integration of importance of determining the susceptibility to quinupristin in order to predict the in vivo activity of quinupristin/dalfopristin pharmacodynamic/pharmacokinetic properties of macrolides. It has been shown that roxithromycin [26] and spiramycin [27] against S. aureus [29]. Entenza et al. [30] compared the therapeutic efficacy of RP were more efficient than erythromycin in pneumococcal infection, through both higher tissue levels and longer t 1/2 b values. 59500 and of vancomycin against rat experimental endocarditis due to either of two erythromycin-susceptible or two constituSimilar results have been obtained with azithromycin vs. erythromycin in two models of acute (Swiss mice) or subacute tively resistant isolates of methicillin-resistant S. aureus. Threeday therapy was initiated 12 hours following infection, and the (C57BL/6 mice) pneumococcal pneumonia [22] . Azithromycin demonstrated a sevenfold higher tissue penetration and a 15-drugs were delivered via a computerized pump, which permitted mimicking of the human serum kinetics produced by a fold longer lung half-life than erythromycin.
Eighteen hours after infection, the AUC for the lungs of b.i.d. iv injection of 7 mg of RP 59500/kg or 1 g of vancomycin.
Both antibiotics cured 70% of infections due to the erythroSwiss mice was twice that for uninfected animals. This can be explained by the trapping of azithromycin in locally recruited mycin-susceptible isolates. Vancomycin was also effective against the constitutively resistant strains, but RP 59500 failed macrophages. Neutropenic animals did not have these increased AUC values [28] . against these isolates. Further experiments proved that RP 59500 failures were related to the very short serum life-span A comparison of five macrolides (erythromycin, roxithromycin, spiramycin, clarithromycin, and azithromycin) in these of dalfopristin (£2 hours, vs. §6 hours for quinupristin), since successful treatment was restored by artificially prolonging the models has established, in standard experimental conditions, that the relative efficacy of macrolides in vivo is related not dalfopristin life span to 6 hours. This observation might be relevant for humans, in whom the serum half-life of dalfopristin only to their penetration into the lung but also to their lung t 1/2 b, which reflects their potential uptake, sequestration, and is also shorter than that of quinupristin. durable delivery at the site of infection [28] .
Similar results have been obtained with azithromycin/ Conclusions erythromycin in a mouse model of H. influenzae pulmonary infection [23] . This supports the notion that macrolides are Integration of pharmacokinetic/pharmacodynamic properties of macrolides, azalides, and streptogramins is an important step targeted antibiotics and reinforces interest in compounds with extended half-life, such as azithromycin, which could demonin the definition of optimal dosing regimens for humans. This preclinical evaluation allows definition of a range of doses to strate increased efficacy despite once-daily administration or allow reduction in the duration of therapy because of the persisbe used in different clinical indications to be tested in human trials. Against extracellular pathogens, the time during which tence of high cellular levels.
With the mouse thigh-infection model, Craig and Ebert have concentrations of free extracellular drug are greater than the MIC is the major determinant of the efficacy of macrolides. shown that in the determination of the dose required to achieve / 9c51$$jy29 06-15-98 21:14:16 cida UC: CID
